TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01263496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study: NCT00780806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal B rLP2086 vaccine candidate
Description: vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw
Study: NCT03908164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertussis containing vaccine
Description: Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertussis containing vaccine
Description: Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertussis containing vaccine
Description: Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
Study: NCT01989416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine wipe
Description: The ICU patients will be bathing with 2% chlorhexidine wipe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soap
Description: The ICU patients will be bathing with Soap
Study: NCT02070809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue-engineered skin method
Description: This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: split-thickness skin graft method
Description: This method is traditional split-thickness skin graft
Study: NCT01841515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin administration
Study: NCT03295409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
Study: NCT01695291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be administered twice a day (BID) for 12 weeks.
Study: NCT03892109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cord
Description: Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingitrac
Description: packed into the sulcus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingitrac
Description: packed into the sulcus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingitrac
Description: packed into the sulcus
Study: NCT04063124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Quercetin
Description: Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
Study: NCT03386500

Intervention type: DRUG
Group type: OTHER
Intervention: BMX-001
Description: BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
Study: NCT00900900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone (DHEA)
Description: one-time 400mg oral dose of DHEA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pregnenolone
Description: one-time 400mg oral dose of pregnenolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one-time dose oral dose
Study: NCT00096499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01230515

Intervention type: OTHER
Intervention: Individual patient interview, focus group and structured survey

Intervention type: OTHER
Intervention: interview, focus group and structured survey

Intervention type: OTHER
Intervention: interview, focus group and structured survey

Intervention type: OTHER
Intervention: interview, focus group and structured survey
Study: NCT04693104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVA Hydrogel
Description: PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisk-One®
Description: Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
Study: NCT01959958

Intervention type: OTHER
Intervention: Questionnaire/Interview
Description: Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
Study: NCT01640340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV(intervenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study: NCT02933073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OncoImmunome
Description: The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
Study: NCT04617418

Intervention type: BEHAVIORAL
Intervention: Change in touchscreen interactions
Description: The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
Study: NCT03836326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor intervention
Description: Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Routine care provided by health professionals in the NICU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story telling attention refocusing intervention
Description: A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
Study: NCT01882049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REALIZE Gastric band (ETHICON)
Description: Placement of gastric band around upper stomach
Study: NCT02059551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI combined with venous ultrasonography of the legs
Description: In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
Study: NCT03892109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingitrac
Description: packed into the sulcus
Study: NCT02850393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Study: NCT04468464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal Splint Treatment
Description: Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal Splint Treatment
Description: Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
Study: NCT02850393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral measures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral measures
Study: NCT04468464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Treatment
Description: Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
Study: NCT02850393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological measurements
Study: NCT03271411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR-based Flash technique
Description: Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-based Flash technique
Description: Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
Study: NCT02477800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037)
Description: Low dose
Study: NCT02071316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hexacapron( Tranexamic acid)
Description: 1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: esomeprazole
Description: 2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
Study: NCT02260154

Intervention type: DRUG
Intervention: Mebeverine
Description: Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
Study: NCT02477800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037)
Description: High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04428762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Port Advance use
Description: participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.
Study: NCT01327586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATM
Description: Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Drug Counseling
Description: Standard individualized drug counseling, modified from that described by Woody and colleagues
Study: NCT04486404

Intervention type: OTHER
Intervention: Online survey
Description: Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).

Intervention type: OTHER
Intervention: Online survey
Description: Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
Study: NCT01693666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group.
Study: NCT00933374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
Study: NCT00129376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT00474539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose at 2,4,6 and 15 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: 1 dose at 2,4,6 and 15 months of age
Study: NCT01858337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green beans group
Description: Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artichoke group
Description: Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple group
Description: Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plums group
Description: Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
Study: NCT02839512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jejunal to Ileal Diversion
Description: The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
Study: NCT02093741

Intervention type: BIOLOGICAL
Intervention: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
Description: The investigators shall determine all treatment regimens according to product labeling information and standard practice.
Study: NCT01920087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATNC05
Description: Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
Study: NCT02061540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Description: LUM001 oral dose
Study: NCT02393612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP-R202
Description: Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R202
Description: Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag tab
Description: Anplag tab 100mg is administrated to patients with PAD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag tab
Description: Anplag tab 100mg is administrated to patients with PAD for 12 weeks
Study: NCT00941707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 38518168
Description: JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
Study: NCT01608555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin
Description: inhaled tobramycin 300 mg single dose OD for 28 days
Study: NCT04669509

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests
Description: Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests
Description: Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests
Description: Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
Study: NCT00597857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: receipt of a placebo pill for 16 days
Study: NCT03378973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
Study: NCT04530318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
Description: The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).